HIKAL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 308.7 INR | -0.98% |
|
+1.83% | +1.71% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 56.68 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +1.71% | 461M | C | ||
| +25.61% | 660B | C+ | ||
| +23.22% | 562B | B | ||
| -5.24% | 358B | C+ | ||
| +16.49% | 322B | B- | ||
| +8.28% | 297B | C+ | ||
| +13.27% | 219B | B+ | ||
| -9.65% | 196B | A+ | ||
| +6.68% | 199B | B- | ||
| -8.75% | 149B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- HIKAL Stock
- Ratings Hikal Limited
